An increasing body of scientific evidence is showing how deeply interconnected the immune, nervous, and endocrine systems are. Autoimmune diseases no longer appear to depend solely on a “local” immune alteration, but rather on a broader dysregulation involving the systems responsible for maintaining the body’s biological balance.
A recent observational clinical study explored this perspective by evaluating the effectiveness of an integrated neuroimmune approach based on melatonin, angiotensin 1-7, and cannabidiol in patients with autoimmune diseases refractory to conventional treatments.
The Role of the Neuro-Immune-Endocrine Network
According to the psychoneuroendocrinoimmunology (PNEI) model, the brain, endocrine system, and immune system constantly communicate through shared biological mediators.
The study highlights the role of several neuroendocrine systems with anti-inflammatory and immunomodulatory functions:
- the pineal gland and melatonin;
- the endocannabinoid system;
- the ACE2 / angiotensin 1-7 axis.
These systems physiologically contribute to regulating inflammation and immune homeostasis. When their activity becomes altered, chronic inflammation and immune dysregulation may emerge.
The Clinical Study
The research involved 70 patients with refractory autoimmune diseases, meaning patients who either did not respond to or could not tolerate conventional immunosuppressive therapies.
The treatment protocol included:
- oral melatonin;
- gastro-protected angiotensin 1-7;
- cannabidiol (CBD).
Researchers evaluated several parameters, including:
- autoantibody levels;
- clinical and radiological disease stability;
- markers of systemic inflammation.
Observed Results
After three months of treatment, significant results were observed.
Patients with Hashimoto’s thyroiditis showed a marked reduction in anti-thyroglobulin antibodies, while patients with other autoimmune diseases experienced a decrease in antinuclear autoantibody levels.
Particularly interesting were the findings related to multiple sclerosis: 62% of patients achieved radiological disease stabilization during follow-up.
Several markers associated with systemic inflammation also improved, suggesting a rebalancing effect on immune regulation. Furthermore, the treatment was well tolerated, with no clinically significant adverse events reported.
A Medicine Focused on Connections
Perhaps the most relevant aspect of this study is not only the clinical outcomes, but the paradigm it represents.
The neuroimmune approach does not focus exclusively on symptoms or isolated organs; instead, it aims to support the biological network connecting immunity, the brain, neuroendocrine rhythms, and inflammation.
This perspective is fully consistent with PNEI, which views health as the result of a dynamic balance among interconnected systems.
Further controlled clinical studies will be needed to confirm these findings, but the direction of research is becoming increasingly clear: understanding and supporting communication among the body’s systems may become one of the most important challenges for the medicine of the future.